+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Treatment of mild non-chemotherapy-induced iron deficiency anemia in cancer patients: comparison between oral ferrous bisglycinate chelate and ferrous sulfate



Treatment of mild non-chemotherapy-induced iron deficiency anemia in cancer patients: comparison between oral ferrous bisglycinate chelate and ferrous sulfate



Biomedicine and PharmacoTherapy 66(6): 414-418



In cancer patients mild-moderate non-chemotherapy-induced iron deficiency anemia (IDA) is usually treated with oral iron salts, mostly ferrous sulfate. In this study, we compare efficacy and toxicity of oral ferrous bisglycinate chelate and ferrous sulfate in cancer patients with mild IDA. Twenty-four patients operated on for solid tumors (10 breast, 12 colorectal, 2 gastric), aged 61±10 years (range 45-75), with non-chemotherapy-induced hemoglobin (Hb) values between 10 and 12 g/dL and ferritin lower than 30 ng/mL were randomized to receive oral ferrous bisglycinate chelate, 28 mg per day for 20 days, and then 14 mg per day for 40 days (12 patients) (A group) or oral ferrous sulphate, 105 mg per day for 60 days (12 patients) (B group). Values of hemoglobin and ferritin obtained at diagnosis, 1 and 2 months from the beginning of treatment were compared. Adverse events (AEs) related to the two treatments were recorded. In the 12 patients treated with ferrous bisglycinate chelate, basal hemoglobin and ferritin values (mean±SD) were 11.6±0.8 g/dL and 16.1±8.0 ng/mL. After 2 months of treatment, they were 13.0±1.4 g/dL and 33.8±22.0 ng/mL, respectively (P=0.0003 and P=0.020). In the group treated with ferrous sulphate, hemoglobin and ferritin mean values were 11.3±0.6 g/dL and 19.0±6.4 ng/mL basally, and 12.7±0.70 g/dL and 40.8±28.1 ng/mL (P<0.0001 and P=0.017) after 2 months of treatment. AEs occurred in six cases. In all these six cases, two (17%) treated with ferrous bisglycinate chelate and four (33%) with ferrous sulphate, toxicity was grade 1. In conclusion, these data suggest that ferrous bisglycinate chelate has similar efficacy and likely lower GI toxicity than ferrous sulphate given at the conventional dose of 105 mg per day for the same time.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 036471158

Download citation: RISBibTeXText

PMID: 22795809

DOI: 10.1016/j.biopha.2012.06.003


Related references

Comparison of ferrous sulfate and ferrous glycinate chelate for the treatment of iron deficiency anemia in gastrectomized patients. Nutrition 24(7-8): 663-668, 2008

Ferrous bisglycinate 25 mg iron is as effective as ferrous sulfate 50 mg iron in the prophylaxis of iron deficiency and anemia during pregnancy in a randomized trial. Journal of Perinatal Medicine 42(2): 197-206, 2014

Comparison of intravenous ferrous sucrose and oral ferrous sulphate in treatment of postpartum iron deficiency anemia. Journal of Maternal-Fetal and Neonatal Medicine 30(8): 967-971, 2017

Comparison of intramuscular iron-dextran and oral ferrous sulfate in the treatment of iron-deficiency anemia. Journal of Pediatrics 54(1): 50-59, 1959

Efficacy of ferrous bis-glycinate versus ferrous glycine sulfate in the treatment of iron deficiency anemia with pregnancy: a randomized double-blind clinical trial. Journal of Maternal-Fetal and Neonatal Medicine 2018: 1-7, 2018

Iron Transport from Ferrous Bisglycinate and Ferrous Sulfate in DMT1-Knockout Human Intestinal Caco-2 Cells. Nutrients 11(3):, 2019

Oral iron absorption test with ferrous bisglycinate chelate in children with celiac disease. Minerva Pediatrica 71(2): 139-143, 2019

Bisglycino-iron (II) chelate (FerrochelReg.) - Part 2. Ferrous bisglycinate chelate. Agro Food Industry Hi Tech 12(5): 14-16, 2001

Mo1226 Comparison Between Liposomial Iron and Ferrous Sulfate in Patients With Iron Deficiency Anemia and Inflammatory Bowel Disease. A Pilot Controlled Study. Gastroenterology 146(5): S-591, 2014

Treatment of iron deficiency anemia in patients with iron intolerance: clinical evaluation of a controlled-release form of ferrous sulfate. Current Therapeutic Research Clinical and Experimental 4: 130-134, 1962

Intravenous iron sucrose complex vs. oral ferrous sulfate for postpartum iron deficiency anemia. International Journal of Gynaecology and Obstetrics: the Official Organ of the International Federation of Gynaecology and Obstetrics 90(3): 238-239, 2005

Intravenous iron sucrose versus oral iron ferrous sulfate for antenatal and postpartum iron deficiency anemia: a randomized trial. Journal of Maternal-Fetal and Neonatal Medicine 26(7): 654-659, 2013

Effectiveness of treatment of iron-deficiency anemia in infants and young children with ferrous bis-glycinate chelate. Nutrition 17(5): 381-384, 2001

Preparation and Bioavailability Analysis of Ferrous Bis Alanine Chelate as a New Micronutrient for Treatment of Iron Deficiency Anemia. Advanced Pharmaceutical Bulletin 6(3): 407-413, 2016

Efficacy of complex Hongyibuxue oral solution and ferrous sulfate for iron deficiency anemia. Di 1 Jun Yi Da Xue Xue Bao 25(6): 732-733, 2005